AAPL 168.0 -0.8147% MSFT 411.84 -0.6609% GOOG 156.88 0.5641% GOOGL 155.47 0.693% AMZN 181.28 -1.1128% NVDA 840.35 -3.8666% META 494.17 -1.1185% TSLA 155.45 -1.0566% TSM 139.03 -0.5508% LLY 750.77 0.5397% V 272.69 0.4938% AVGO 1282.63 -3.4934% JPM 180.08 -0.3982% UNH 478.99 2.154% NVO 124.53 0.8748% WMT 59.65 -0.3175% LVMUY 170.745 -0.914% XOM 118.65 -0.0337% LVMHF 858.0 0.345% MA 460.16 0.0739%
Last update at 2024-04-17T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -85.47400M | -88.44100M | 7.72M | -107.18900M | -74.40200M |
| Minority interest | - | - | - | - | - |
| Net income | -83.41300M | -88.19300M | 8.41M | -106.37300M | -74.01300M |
| Selling general administrative | 30.26M | 29.41M | 21.75M | 17.75M | 15.32M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 34.60M | 23.03M | 135.08M | 19.89M | 13.47M |
| Reconciled depreciation | 0.25M | 0.25M | 0.21M | 0.20M | 0.37M |
| Ebit | -87.78300M | -89.33100M | 5.38M | -111.87700M | -77.75200M |
| Ebitda | -87.53500M | -89.08300M | 5.59M | -111.67900M | -77.38200M |
| Depreciation and amortization | 0.25M | 0.25M | 0.21M | 0.20M | 0.37M |
| Non operating income net other | 2.06M | 0.64M | 2.33M | 4.49M | 2.98M |
| Operating income | -87.53500M | -89.08300M | 5.38M | -111.67900M | -77.38200M |
| Other operating expenses | 129.40M | 112.11M | 129.70M | 131.56M | 90.85M |
| Interest expense | -0.24800M | 0.25M | 2.33M | 4.69M | 0.00000M |
| Tax provision | 0.00000M | 0.00000M | -0.69100M | -0.81600M | -0.38900M |
| Interest income | - | - | - | 4.49M | 2.98M |
| Net interest income | - | - | - | - | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -2.06100M | -0.24800M | -0.69100M | -0.81600M | -0.38900M |
| Total revenue | 41.87M | 23.03M | 135.08M | 19.89M | 13.47M |
| Total operating expenses | 122.14M | 112.11M | 129.70M | 131.56M | 90.85M |
| Cost of revenue | 7.27M | - | - | 113.82M | 75.53M |
| Total other income expense net | 2.06M | 0.64M | 2.33M | 4.49M | 2.98M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -85.47400M | -88.44100M | 8.41M | -106.37300M | -74.01300M |
| Net income applicable to common shares | -85.47400M | -88.44100M | 8.41M | -106.37300M | -74.01300M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 182.24M | 247.06M | 271.16M | 232.96M | 190.82M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 16.68M | 2.52M | 13.58M | 9.68M | 5.17M |
| Total liab | 23.46M | 19.53M | 22.16M | 46.25M | 57.19M |
| Total stockholder equity | 158.78M | 227.52M | 249.00M | 186.71M | 133.63M |
| Deferred long term liab | - | - | - | - | 1.56M |
| Other current liab | 11.94M | 10.24M | 11.99M | 10.56M | 9.25M |
| Common stock | 0.05M | 0.05M | 0.05M | 0.05M | 0.04M |
| Capital stock | 0.05M | 0.05M | 0.05M | 0.05M | 0.04M |
| Retained earnings | -566.23200M | -480.75800M | -392.31700M | -400.72700M | -294.35400M |
| Other liab | - | - | - | - | 16.75M |
| Good will | - | - | - | - | - |
| Other assets | - | 0.41M | 0.41M | 0.41M | 0.41M |
| Cash | 63.74M | 13.45M | 31.68M | 18.30M | 15.08M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 23.46M | 17.62M | 18.48M | 42.89M | 40.45M |
| Current deferred revenue | - | - | - | 22.26M | 26.82M |
| Net debt | -61.82300M | -9.78000M | -26.40800M | -13.98600M | -15.08100M |
| Short term debt | 1.92M | 1.75M | 1.60M | 0.97M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 1.92M | 3.67M | 5.28M | 4.32M | - |
| Other stockholder equity | 726.63M | 708.59M | 641.20M | 587.22M | 428.06M |
| Property plant equipment | 0.43M | 0.63M | 0.84M | 0.70M | 0.88M |
| Total current assets | 168.91M | 173.29M | 195.06M | 165.66M | 168.14M |
| Long term investments | 11.35M | 69.75M | 70.56M | 63.16M | 21.40M |
| Net tangible assets | 158.78M | 229.44M | 252.67M | 190.06M | 148.81M |
| Short term investments | 81.66M | 153.58M | 149.24M | 136.70M | 146.30M |
| Net receivables | 4.45M | 1.15M | 2.06M | 1.79M | 1.59M |
| Long term debt | - | - | - | - | - |
| Inventory | 2.38M | 2.58M | -1.50700M | -0.81600M | - |
| Accounts payable | 9.60M | 5.62M | 4.89M | 9.10M | 4.37M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1.67200M | -0.35800M | 0.07M | 0.17M | -0.11400M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.05M | 0.05M | 0.05M | 0.05M | 0.04M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -566.23200M | -480.75800M | -392.31700M | -400.72700M | -294.35400M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 12.90M | 0.41M | 0.41M | 0.41M | 0.41M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 13.33M | 73.77M | 76.09M | 67.30M | 22.68M |
| Capital lease obligations | 1.92M | 3.67M | 5.28M | 4.32M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 124.75M | -25.28200M | -46.96100M | -32.49800M | -82.74600M |
| Change to liabilities | 5.68M | -1.02000M | -2.78400M | 6.04M | 5.12M |
| Total cashflows from investing activities | 128.71M | -4.75100M | -20.27500M | -30.51600M | -82.81900M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 0.31M | 46.61M | 39.14M | 142.60M | 110.81M |
| Change to operating activities | -15.54400M | 7.96M | -4.30600M | -4.93700M | -3.17000M |
| Net income | -85.47400M | -88.44100M | 8.41M | -106.37300M | -74.01300M |
| Change in cash | 50.29M | -18.23000M | 13.38M | 2.86M | 5.69M |
| Begin period cash flow | 13.86M | 32.09M | 18.71M | 15.85M | 10.16M |
| End period cash flow | 64.15M | 13.86M | 32.09M | 18.71M | 15.85M |
| Total cash from operating activities | -78.73000M | -60.08700M | -5.48700M | -109.22500M | -22.30100M |
| Issuance of capital stock | 0.00000M | 44.97M | 38.45M | 136.50M | 106.62M |
| Depreciation | 0.25M | 0.25M | 0.21M | 0.20M | 0.37M |
| Other cashflows from investing activities | 4.00M | 20.57M | 27.04M | 2.00M | -82.74600M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 0.20M | -2.58400M | -2.58400M | -2.58400M | -2.58400M |
| Change to account receivables | -3.26000M | 1.02M | -0.69100M | -0.04500M | -0.80300M |
| Sale purchase of stock | 0.31M | 1.64M | 0.69M | 142.60M | 96.26M |
| Other cashflows from financing activities | 128.71M | 1.64M | 0.69M | 6.11M | 4.19M |
| Change to netincome | 17.73M | 20.71M | 14.84M | 12.57M | 9.48M |
| Capital expenditures | 0.04M | 0.04M | 0.35M | 0.02M | 0.07M |
| Change receivables | -3.30100M | 0.10M | 0.41M | -0.04500M | -0.80300M |
| Cash flows other operating | -14.08100M | 10.03M | -26.72500M | -20.23500M | 39.37M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 50.29M | -18.23000M | 13.38M | 2.86M | 5.69M |
| Change in working capital | -12.92400M | 5.26M | -29.62900M | -18.83800M | 43.22M |
| Stock based compensation | 17.73M | 20.79M | 14.84M | 12.57M | 9.48M |
| Other non cash items | 1.69M | 1.31M | 0.81M | 4.60M | 0.46M |
| Free cash flow | -78.77300M | -60.12600M | -5.83600M | -109.24300M | -22.37400M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CARA Cara Therapeutic |
0.02 3.23% | 0.73 | - | - | 1.56 | 0.38 | 12.05 | 0.32 |
| NVO Novo Nordisk A/S |
1.08 0.87% | 124.53 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.41 1.15% | 124.15 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-1.07 0.27% | 393.10 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
0.13 0.15% | 87.96 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.
4 Stamford Plaza, Stamford, CT, United States, 06902
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher A. Posner | Pres, CEO & Director | 1970 |
| Dr. Derek T. Chalmers D.Sc., Ph.D. | Co-Founder & Sr. Advisor | 1964 |
| Dr. Frédérique Menzaghi | Chief Scientific Officer and Sr. VP of R&D | 1966 |
| Mr. Scott M. Terrillion | Chief Compliance Officer, Gen. Counsel & Corp. Sec. | 1963 |
| Dr. Joana Goncalves | Chief Medical Officer | 1974 |
| Mr. Ryan D. Maynard | Chief Financial Officer | 1969 |
| Dr. Iris Francesconi Ph.D. | Chief Strategy Officer & Head of Investor Relations | NA |
| Mr. Eric Vandal | Sr. VP of Commercial | NA |
| Ms. Beth Weinberg | Sr. VP of Regulatory Affairs & QA | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...